Every 10-Q that Agilent Technologies Inc. (A) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow A and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full A filings page.
Agilent Technologies, Inc. (A) reported higher sales and earnings for the three and nine months ended July 31, 2026, while executing a sizeable acquisition and adding new debt. Quarterly net revenue was $1.878 billion, up from $1.738 billion a year earlier, and net income was $362 million versus $336 million. Diluted EPS rose to $1.28 from $1.18 as operating income improved to $444 million, reflecting stronger product and service revenues across regions and end markets.
For the first nine months, revenue grew to $5.511 billion from $5.087 billion and net income to $1.006 billion from $869 million, supported by solid operating cash flow of $1.064 billion. Agilent closed the $950 million acquisition of Biocare, expanding its pathology offering, and issued $600 million of 2032 senior notes, increasing long-term debt to $3.645 billion while ending the period with $1.758 billion of cash. The company continued share repurchases and paid $0.765 per share in dividends year-to-date, and is incurring restructuring charges to streamline its organization. Management also notes uncertainty around potential tariff refunds and geopolitical tensions, though these had no material impact through the third quarter.
Agilent Technologies reported stronger quarterly results with solid growth and profitability. For the three months ended April 30, 2026, net revenue rose to $1.835 billion from $1.668 billion, driven by higher product and service sales across Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets. Net income increased to $339 million from $215 million, with diluted EPS of $1.20 versus $0.75 a year earlier.
For the first six months of fiscal 2026, revenue reached $3.633 billion and net income $644 million. Agilent ended the quarter with $1.807 billion in cash and cash equivalents and total assets of $13.065 billion, against total liabilities of $5.943 billion. The company announced a pending acquisition of Biocare for approximately $950 million in cash, continued its 2024 share repurchase program, and paid dividends of $0.510 per share year-to-date while maintaining significant borrowing capacity under its credit facilities and commercial paper program.
Agilent Technologies reported net revenue of $1,798 million for the quarter ended January 31, 2026, up 7% from $1,681 million a year earlier, with growth across all three segments and all regions. Life Sciences and Diagnostics Markets revenue rose 5%, Agilent CrossLab 9%, and Applied Markets 7%, helped by a favorable foreign currency impact of up to 3% on segment growth.
Net income was $305 million, down slightly from $318 million, and diluted EPS was $1.07 versus $1.11. Operating income was $353 million, after $89 million of unallocated costs including amortization, restructuring, and transformation expenses. Cash from operations declined to $268 million from $431 million, reflecting working capital swings and compensation payments, but cash and cash equivalents remained strong at $1,758 million.
The company continued returning capital, paying a quarterly dividend of $0.255 per share (about $72 million) and repurchasing 1.05 million shares for $152 million under its 2024 buyback program. Management notes tariff-related cost pressure but expects to offset this during fiscal 2026 through supply chain changes, pricing, and efficiency initiatives.
Agilent Technologies (A) reported condensed, unaudited quarterly results for the three and nine months ended July 31, 2025, prepared under U.S. GAAP and recast to reflect a new three-segment structure: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.
Services and other revenue grew 11% for the quarter and 9% year-to-date, driven by contract repair, preventative maintenance and on-demand services. Income from operations rose $4 million (3%) for the quarter and $21 million (6%) year-to-date on revenue increases, while operating margins faced near-term pressure from increased tariffs, shipping costs, unfavorable mix, warranty and variable pay. No goodwill impairment was indicated after quantitative testing. The company repurchased shares under its repurchase programs and paid quarterly dividends; commercial paper outstanding was $55 million at a 4.55% weighted average rate.